Disease landscape

Melanoma clinical trials

Get alerts when Melanoma trials change

808 active trials 444 recruiting 64 Phase 3 414 sponsors 108 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-08-28

What changed in the last 30 days showing 51 of 108 changes on 20 trials

2026-08-25
Trial terminated
Primary completion moved earlier: 2028-12-31 → 2026-07-01
Completion moved earlier: 2029-12-31 → 2026-07-31
NCT07193966 NG2 and DLL3 CAR-T Cells Targeting Melanoma · Shenzhen Geno-Immune Medical Institute · Phase 1/2
2026-08-13
Trial terminated
Trial terminated: PI opted to close study due to poor accrual.
Completion moved earlier: 2027-06 → 2025-08-11
NCT05308901 Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve… · Providence Health & Services · Phase 2
2026-08-04
Trial terminated
Trial terminated: The study was terminated prematurely due to insufficient patient recruitment
Enrollment reduced: 670 → 152 participants
NCT03412058 Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists · UNICANCER
2026-07-31
Primary completion pushed: 2026-06-12 → 2027-02-28
Completion pushed: 2026-06-12 → 2027-02-28
NCT05267626 Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in… · Aulos Bioscience, Inc. · Phase 1/2
2026-07-30
Primary completion pushed: 2026-10-30 → 2033-07
Primary endpoint(s) modified
Enrollment reopened
Enrollment increased: 296 → 340 participants
Completion pushed: 2027-05-12 → 2033-07
Trial arms changed: 14 → 15
NCT04198766 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in… · Inhibrx Biosciences, Inc · Phase 1/2
2026-07-30
Primary completion pushed: 2025-06-06 → 2028-10-19
Enrollment increased: 150 → 180 participants
Completion pushed: 2026-07-31 → 2028-10-19
NCT06081920 A Study of IBI363 in Subjects With Advanced Melanoma · Innovent Biologics (Suzhou) Co. Ltd. · Phase 2
2026-08-25
Primary completion pushed: 2026-06-30 → 2027-06-30
Completion pushed: 2027-12-31 → 2028-12-31
NCT05034536 PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma · Massachusetts General Hospital · Phase 2
2026-08-27
Primary endpoint(s) modified
NCT05625399 A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously… · Bristol-Myers Squibb · Phase 3
2026-08-21
Primary completion pushed: 2026-08-31 → 2028-08-31
Completion pushed: 2026-08-31 → 2028-08-31
NCT01644591 Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain… · M.D. Anderson Cancer Center · Phase 2
2026-08-12
Primary completion pushed: 2018-02-10 → 2021-09-09
Trial completed
Completion moved earlier: 2027-03-04 → 2021-09-09
NCT02581930 Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma · National Cancer Institute (NCI) · Phase 2
2026-08-21
Primary completion pushed: 2024-05-17 → 2026-10-07
Primary endpoint(s) modified
Enrollment closed, study ongoing
Completion pushed: 2027-05-31 → 2027-08-05
NCT04572451 Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in… · Yana Najjar · Phase 1
2026-08-20
Primary completion pushed: 2026-07-15 → 2028-02-03
Completion pushed: 2026-11-24 → 2028-02-03
NCT03454035 Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors · UNC Lineberger Comprehensive Cancer Center · Phase 1
2026-08-20
Primary completion pushed: 2026-07-31 → 2027-07-31
Completion pushed: 2027-03-31 → 2027-07-31
NCT06298734 High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma… · Fred Hutchinson Cancer Center
2026-08-12
Primary completion pushed: 2026-07 → 2027-03
Completion pushed: 2026-07 → 2027-03
NCT04588662 A Prospective Natural History Study in Uveal Melanoma · Columbia University
2026-08-06
Primary completion pushed: 2026-07 → 2027-07
Completion pushed: 2026-07 → 2027-07
NCT00591500 A Model for Genetic Susceptibility: Melanoma · Memorial Sloan Kettering Cancer Center
2026-08-21
Primary endpoint(s) modified
Trial arms changed: 4 → 5
NCT05269381 Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for… · Mayo Clinic · Phase 1/2
2026-08-01
Primary endpoint(s) modified
NCT07628634 Feasibility Study on the Effect of a Methionine-Reduced Diet on Serum Levels in Pts w/… · University of California, Irvine · Early Phase 1
2026-07-31
Primary endpoint(s) modified
Enrollment reduced: 250 → 118 participants
Enrollment closed, study ongoing
NCT07259304 Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors · University of Southern California
2026-08-07
Enrollment reduced: 450 → 165 participants
Enrollment closed, study ongoing
Trial sites reduced: 41 → 36 locations
NCT05581004 A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single… · Genentech, Inc. · Phase 1
2026-08-22
Enrollment reduced: 10 → 7 participants
Trial completed
NCT06549439 eFLASH for Skin Lesions of Malignant Melanomas · University of Zurich

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-08-26 NCT07788729 Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their… University of Regensburg new
2026-08-12 NCT07760012 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors Peking University Third Hospital new
2026-08-11 NCT07757386 MelaMEd Online Training for General Practitioners to Improve Melanoma Detection and… Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS new
2026-08-05 NCT07747935 Study of Neoadjuvant RBP-01 In Patients With Primary Uveal Melanoma ReBio Pharma new Phase 1/2
2026-07-22 NCT07720726 Impact of Dysport on PMFF Donor Scar Vanderbilt University Medical Center new Phase 4
2026-07-21 NCT07718243 Investigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours, Melanoma… Institute of Cancer Research, United Kingdom new Phase 1/2
2026-07-15 NCT07704918 Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma University of Colorado, Denver new
2026-07-13 NCT07700121 PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma Abramson Cancer Center at Penn Medicine new Early Phase 1
2026-07-08 NCT07691255 MELanoma Brain Metastasis Treated With CYberknife European Institute of Oncology new
2026-07-07 NCT07686835 Dietary Fiber to Induce Gut Microbiota-mediated Response to Immunotherapy in Melanoma. Radboud University Medical Center new Phase 2

Active trials by phase

Early Phase 1
15
Phase 1
144
Phase 1/2
108
Phase 2
198
Phase 2/3
12
Phase 3
52
Phase 4
8
Not charted: 271 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 808

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Novartis Pharmaceuticals Recruiting 2026-08-25
NCT07405086 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… OHSU Knight Cancer Institute Recruiting 2026-06-12
NCT07445022 RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma Fudan University Recruiting 2026-03-03
NCT07720726 Impact of Dysport on PMFF Donor Scar Vanderbilt University Medical Center Not Yet Recruiting 2026-08-26
NCT07459543 A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose… Bristol-Myers Squibb Not Yet Recruiting 2026-08-12
NCT07004335 Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With… Hebei Medical University Fourth Hospital Not Yet Recruiting 2025-06-04
NCT06785974 Statins to Prevent Immune Checkpoint Inhibitor-induced PRogression of AtherosLerosis Erasmus Medical Center Not Yet Recruiting 2025-01-22
NCT02068196 A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma. Oslo University Hospital Active, Not Recruiting 2023-03-24
Phase 3
NCT06246916 A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants… Regeneron Pharmaceuticals Recruiting 2026-08-19
NCT06743126 SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated… Immatics US, Inc. Recruiting 2026-08-18
NCT06500455 Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients… NRG Oncology Recruiting 2026-08-17
NCT06264180 VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1… Replimune, Inc. Recruiting 2026-07-15
NCT06246149 Adjuvant Tebentafusp in High Risk Ocular Melanoma European Organisation for Research and Treatment of Cancer - EORTC Recruiting 2026-06-30
NCT05727904 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab… Iovance Biotherapeutics, Inc. Recruiting 2026-06-26
NCT02821013 Duration of Anti-PD-1 Therapy in Metastatic Melanoma Canadian Cancer Trials Group Recruiting 2026-06-09
NCT07015190 Neoadjuvant Darovasertib in Primary Uveal Melanoma IDEAYA Biosciences Recruiting 2026-05-06
NCT05522660 Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients… ETOP IBCSG Partners Foundation Recruiting 2026-04-27
NCT07530887 NO Re-excision MelanomA - NORMA 2 Marieke Goodijk Recruiting 2026-04-15
NCT06488482 Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma Uppsala University Recruiting 2026-03-09
NCT05549297 Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma… Immunocore Ltd Recruiting 2026-02-25
NCT06112314 IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma… Immunocore Ltd Recruiting 2026-02-25
NCT07221734 Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus… mAbxience Research S.L. Recruiting 2026-01-21
NCT03567889 Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D… Philogen S.p.A. Recruiting 2025-12-17
NCT06794775 SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in… Hildur Helgadottir Recruiting 2025-12-12
NCT05868707 OH2 Injection in Melanoma Binhui Biopharmaceutical Co., Ltd. Recruiting 2025-07-25
See all 808 active Melanoma trials with filters →

Top sponsors by active trials in this area

M.D. Anderson Cancer Center (42) · National Cancer Institute (NCI) (39) · Memorial Sloan Kettering Cancer Center (19) · H. Lee Moffitt Cancer Center and Research Institute (13) · University Health Network, Toronto (13) · Melanoma Institute Australia (9) · Bristol-Myers Squibb (8) · Institute of Oncology Ljubljana (8) · Mayo Clinic (8) · Vastra Gotaland Region (8)

Get alerts when Melanoma trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free